ROLE OF CONTRACEPTION IN IMPROVING WOMEN´S QUALITY OF LIFE ASSOCIATED WITH PMS AND OTHER MENSTRUAL DISORDERS

Objective – to assess the quality of life (QOL) of women with premenstrual syndrome (PMS) from moderate to severe degree in combination with other symptoms of the menstrual cycle with use of the combined oral contraceptive containing 20 mcg of ethinyl estradiol (EE) and 3 mg of drospirenone (DRSP) under scheme 24/4.

Material and methods. A single-center, prospective, cohort, non-randomized, uncontrolled study was conducted. On the basis of screening of 360 women 27 patients with PMS of moderate and severe forms were selected. The control group consisted of 18 women without PMS. Diagnosis of PMS was based on standardized ICD-10 criteria, the psychological state was assessed by the hospital anxiety and depression scale HADS, QOL index – by the short form of the SF-36 questionnaire. The evaluation was carried out twice – before beginning treatment and in 3 months after the treatment.

Results. Assessment of QOL showed that as compared with the baseline parameters they significantly improved in 3 months of treatment by scales that assess PP (physical pain: 56.0 ± 28.9 vs 76.2 ± 18.9, p = 0.020), RE (role of emotional problems in limitation of life activity: 57.8 ± 21.3 vs 77.9 ± 18.3, p = 0.040), SA (social activity: 42.5 ± 13,5 vs 72,5 ± 12,8, p = 0.050) and MH (mental health: 62,0  ± 7,3 vs 72.0  ± 6.3, p = 0.048).  88.4% of the subjects expressed high satisfaction with the treatment results.

Conclusion. Symptoms of PMS and other disorders of the menstrual cycle successfully stopped for 3 months by a combination of 20EE/DRSP, which is accompanied by a reduction in the incidence of anxiety and depression and improving in QOL.

1. Orley J, Kuyken W. The Development of the World Health Organization Quality of Life Assessment Instrument (the WHOQOL). In: Quality of Life: International Perspectives. Division of Mental Health, World Health Organization. Proceedings of the Joint-Meeting Organized by the World Health Organization and the Fondation IPSEN in Paris, July 2–3, 1993: 41-57.

2. Kind P, Williams A. Measuring success in health care – the time has come to do it properly. Health Policy Matter, 2004, Issue 9: 1-8.

3. Проценко А.С., Абишев Р.Э. Современные тенденции оценки эффективности медицинской помощи через критерий качества жизни. «Современная медицина: тенденции развития»: материалы международной научно-практической конференции. 02 апреля 2012 г. Новосибирск: Изд. «Сибирская ассоциация консультантов», 2012. 132 с./Protsenko A.S., Abishev R.E. Modern trends of medical aid effectiveness evaluation through life quality criterion. Modern Medicine: Development Trends: materials of the international scientific and practical conference. April 02, 2012, Novosibirsk: Ed. Siberian Consultant Association, 2012, 132 p.

4. Дикке Г.Б. Медикаментозный аборт: Руководство для врачей. Под ред. В.Е. Радзинского. М.: МЕДпресс-информ, 2015. 344 с.: ил./Dikke G.B. Mediсation-induced abortion: Guidance for doctors. Ed. by V.E. Radzinsky. M: MEDpressinform, 2015. 344 p.: il.

5. Delara M, Ghofranipour F, Azadfallah P et al. Health related quality of life among adolescents with premenstrual disorders: a cross sectional study. Health and Quality of Life Outcomes, 2012, 10(1): 1-5.

6. Kannan P, Chapple CM, Miller D et al. Menstrual pain and quality of life in women with primary dysmenorrhea: Rationale, design, and interventions of a randomized controlled trial of effects of a treadmill-based exercise intervention. Contemp Clin Trials, 2015, 42: 81-9.

7. Xu L, Lee BS, Asif S. Satisfaction and health-related quality of life in women with heavy menstrual bleeding; results from a non-interventional rial of the levonorgestrel-releasing intrauterine system or conventional medical therapy. International Journal of Women’s Health, 2014, 6: 547-554.

8. Kadir RA, Edlund M, Von Mackensen S. The impact of menstrual disorders on quality of life in women with inherited bleeding disorders. Haemophilia, 2010, 16(5): 832-9.

9. Arowojolu AO, Gallo MF, Lopez LM, Grimes DA. Combined oral contraceptive pills for treatment of acne (Review). The Cochrane Library, 2012, Issue 7. Electronic resource. Access mode: http://onlinelibrary.wiley.com/

10. Latthe P, Mignini L, Gray R, Hills R, Khan K. Factors predisposing women to chronic pelvic pain: systematic review. BMJ, 2006, 332(7544): 749-755.

11. Wang C, Di W, Liao Q, et al. Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 μg in a 24+4-day regimen in China. Zhonghua Fu Chan Ke Za Zhi, 2014, 49(5): 355-9.

12. Lawrie TA, Helmerhorst FM, Maitra NK, Kulier R, Bloemenkamp K, Gülm ezoglu AM. Types of progestogens in combined oral contraception: effectiveness and side-effects (Review). The Cochrane Library, 2011, Issue 5. Electronic resource. Access mode: http://onlinelibrary.wiley.com/

13. Marr J, Heinemann K, Kunz M, Rapkin A. Ethinyl estradiol 20 μg/drospirenone 3mg 24/4 oral contraceptive for the treatment of functional impairment in women with premenstrual dysphoric disorder. Int J Gynaecol Obstet, 2011, 113(2): 103-7.

14. Foidart JM, Wuttke W, Bouw GM et al. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur. J. Contracept. Reprod. Hlth Care, 2000, 5(2): 124-134.

15. Артымук Н.В., Букреева Е.Л. Сравнительная оценка влияния сочетания 3 мг дроспиренона и 20 или 30 мкг этинилэстрадиола на состояние кожи и антропометрические показатели. Фарматека, 2015, 3: 31-33. /Artymuk N.V., Bukreeva E.L. Comparative evaluation of effect of a combination of 3 mg of drospirenonand 20 or 30 mcg of ethinyl estradiol on the skin stat and antropometric values. Farmateka, 2015, 3: 31-33.

16. van Vloten WA, van Haselen CW, van Zuuren EJ et al. The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis, 2002, 69(4): 2-15.

17. Maloney JM, Dietze P, Jr, Watson D, et al. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial. Obstet Gynecol, 2008, 112(4): 773-781.

18. Басова О.Н., Волков В.Г. Сравнительная характеристика эффективности комбинированных оральных контрацептивов в терапии ПМС: рандомизированное контролируемое исследование. Проблемы репродукции, 2011, 4: 27-31./ Basova O.N., Volkov V.G. Comparative characteristics of effectiveness of combined oral contraceptives in PMS therapy: a randomized controlled study. Problemy reproduktsii, 2011, 4: 27-31.

19. Rapkin AJ. YAZ in the treatment of premenstrual dysphoric disorder. J. Reprod. Med., 2008, 53(9): 729-741.

20. Прилепская В.Н., Межевитинова Е.А., Сасунова Р.А. и др. Результаты клинического применения препарата, содержащего дроспиренон, у женщин с тяжелой формой предменструального синдрома. Акуш. и гин., 2012, 2: 81-85./Prilepskaya V.N., Mezhevitinova E.A., Sasunova R.A. et al. Results of clinical administration of the drospirenon-containing drug in women with a grave degree of premenstrual syndrome. Akush. I Gin., 2012, 2: 81-85.

21. Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome (Review). The Cochrane Library, 2012, Issue 2. Electronic resource. Access mode: http://onlinelibrary.wiley.com/

22. Wong CL, Farquhar C, Roberts H, Proctor M. Oral contraceptive pill for primary dysmenorrhoea (Review). The Cochrane Library, 2009, Issue 4. Electronic resource. Access mode: http://onlinelibrary.wiley.com/

23. Skrzypulec V, Drosdzol A. Evaluation of the quality of life and sexual functioning of women using a 30-μg ethinyloestradiol and 3-mg drospirenone combined oral contraceptive. The European Journal of Contraception & Reproductive Health Care, 2008, 13(1): 49-57.

24. Rapkin AJ, Winer SA. Premenstrual syndrome and premenstrual dysphoric disorder: quality of life and burden of illness. Expert Rev Pharmacoecon Outcomes Res, 2009, 9(2): 157-70.

25. Gokyildiz S, Aslan E, Beji NK et al. The Effects of Menorrhagia on Women’s Quality of Life: A Case-Control Study. Obstetrics and Gynecology, 2013, 8: 918179.

26. Iacovides S, Avidon I, Baker FC. What we know about primary dysmenorrhea today: a critical review. Hum Reprod Update, 2015, 21(6): 762-78.

27. Matteson KA, Raker CA, Clark MA et al. Abnormal Uterine Bleeding, Health Status, and Usual Source of Medical Care: Analyses Using the Medical Expenditures Panel Survey. J Womens Health (Larchmt), 2013, 22(11): 959-965.

28. Delara M, Ghofranipour F, Azadfallah P et al. Health related quality of life among adolescents with premenstrual disorders: a cross sectional study. Health and Quality of Life Outcomes, 2012, 10(1): 1-5.

29. Matsumoto Y, Yamabe S, Ideta K, Kawabata M. Impact of use of combined oral contraceptive pill on the quality of life of Japanese women. J Obstet Gynaecol Res, 2007, 33(4): 529-35.

30. Cinar N, Harmanci A, Demir B, Yildiz BO. Effect of an oral contraceptive on emotional distress, anxiety and depression of women with polycystic ovary syndrome: a prospective study. Hum Reprod, 2012, 27(6): 1840-5.

31. Endrikat J, Parke S, Trummer D et al. Ovulation inhibition with four variations of a four-phasic estradiol valerate/ dienogest combined oral contraceptive: results of two prospective, randomized, openlabel studies. Contraception, 2008, 78(3): 218-25.

32. Ahrendt HJ, Makalova D, Parke S et al. Bleeding pattern and cycle control with an estradiolbased oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception, 2009, 80(5): 436-44.

33. Fu Y, Mi W, Li L et al. Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 μg in the treatment of premenstrual dysphoric disorder: a randomized, double blind placebo-controlled study. Zhonghua Fu Chan Ke Za Zhi, 2014, 49(7): 506-9.

34. Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrin Metab, 1995, 8: 1816-21.

35. Nakajima ST, Archer DF, Ellman H. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g (Loestrin 24 Fe). Contraception, 2007, 75: 16-22.

36. Karakhalis LY, Zhigalenko AR, Steblo YeI. Kontratseptivnyye i nekontratseptivnyye effekty drospirenona. Reproduktivnoye zdorov’ye detey i podrostkov, 2015, 2: 73-77.

37. Wang C, Di W, Liao Q, et al. Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 μg in a 24+4-day regimen in China. Zhonghua Fu Chan Ke Za Zhi, 2014, 49(5): 355-9.

38. Nappi RE, Albani F, Tonani S et al. Psychosexual well-being in women using oral contraceptives containing drospirenone. Funct. Neurol. Funct Neurol, 2009, 24(2): 71-75.